The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Signs of an inflammatory process, in particular increased pro-inflammatory cytokines and increased levels of prostaglandine E(2) (PGE(2)), have repeatedly been described in major depression (MD). As cyclooxygenase-2 (COX-2) inhibitors inhibit the PGE(2) production and the production of pro-inflammatory cytokines, we performed a therapeutic trial with the COX-2 inhibitor celecoxib. In a prospective, double-blind, add-on study, 40 patients suffering from an acute depressive episode were randomly assigned to either reboxetine and celecoxib or to reboxetine plus placebo. After a wash-out period, 20 patients received 4-10 mg reboxetine plus placebo and 20 received reboxetine plus 400 mg celecoxib for 6 weeks. The treatment effect was calculated by analysis of variance. There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or reboxetine dose or plasma levels. Over 6 weeks, both groups of patients showed significant improvement in scores of the Hamilton Depression Scale. However, the celecoxib group showed significantly greater improvement compared to the reboxetine-alone group. Additional treatment with celecoxib has significant positive effects on the therapeutic action of reboxetine with regard to depressive symptomatology. Moreover, the fact that treatment with an anti-inflammatory drug showed beneficial effects on MD indicates that inflammation is related to the pathomechanism of the disorder, although the exact mechanisms remain to become elucidated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients in the reboxetine plus celecoxib group exhibited reductions in depression severity that were nearly twice as great (55% reduction) as those experienced by patients in the control group (33% reduction).”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“75% of patients receiving reboxetine plus celecoxib were categorized as responders, compared to only 45% of patients receiving reboxetine plus placebo”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“TNFα antagonists such as etanercept or infliximab and the COX-2 inhibitor celecoxib have all been found to alleviate depressive symptoms in double-blind, randomized, placebo-controlled studies”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“One study found positive effects on mood in medically healthy, major depressed patients.52”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [52]
In the citing paper
“from the administration of COX2 inhibitors to patients with major depression81”
From From inflammation to sickness and depression: when the immune system subjugates the brain (2008) · cites this paper as [81]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The global burden of disease, 1990–2020
Lopez, A. D., & Murray, C. C. J. L. (1998) · Nature Medicine · doi:10.1038/3218 · Cited by 1,614
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997) · Cytokine · doi:10.1006/cyto.1997.0238 · Cited by 728
Maes, M., Scharpé, S., Meltzer, H. Y., Bosmans, E., Suy, E., Calabrese, J., & Cosyns, P. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90027-e · Cited by 439
Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H.-J., & Schwarz, M. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1029 · Cited by 388
Self-citationFrommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362
Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2004) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2003.11.004 · Cited by 236
Song, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00025-1 · Cited by 232
Cited by
Items 401–500 of 802
Tenenbaum, M., Azab, A. N., & KAPLANSKI, J. (2007) · Journal of Endotoxin Research · doi:10.1177/0968051907080428 · Cited by 38
Pathologic role of nitrergic neurotransmission in mood disorders
Ghasemi, M., Claunch, J. D., & Niu, K. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.06.002 · Cited by 38
Raison, C. L. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_26 · Cited by 36
“conducted a welldesigned and described study that has received significant attention since its publication in 2006 [43].”
BackgroundZhang, J., Yue, Y., Thapa, A., Fang, J., Zhao, S., Shi, W., Yang, Z., Li, Y., & Yuan, Y. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.001 · Cited by 35
Cheng, J.-H., Xu, X. M., Li, Y.-B., Zhao, X., Aosai, F., Su-yun, S., Jin, C. H., Piao, J., Ma, J., Piao, H., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106302 · Cited by 38
The fiery landscape of depression: A review of the inflammatory hypothesis
Hashmi, A. M., Aftab, A., Mazhar, N., Umair, M., & Butt, Z. (2013) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.293.3357 · Cited by 40
Hayley, S. P., Mangano, E. N., Strickland, M., & Anisman, H. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.03.015 · Cited by 37
Anti-inflammatory treatment and risk for depression
Wium‐Andersen, I. K., Wium‐Andersen, M. K., Jørgensen, M. B., & Osler, M. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn160244 · Cited by 37
Is major depressive disorder a metabolic encephalopathy?
Harvey, B. H. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.946 · Cited by 36
Immunologische Aspekte bei depressiven Störungen
Müller, N., & Schwarz, M. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2311-3 · Cited by 48
Self-citation(2013) · Durham Research Online (Durham University) · Cited by 35
Vizlin‐Hodzic, D., Zhai, Q., Illes, S., Södersten, K., Truvé, K., Parris, T. Z., Sobhan, P. K., Salmela, S., Kosalai, S. T., Kanduri, C., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.284 · Cited by 37
Prognostic Implications of Depression and Inflammation in Patients With Metastatic Lung Cancer
McFarland, D. C., Saracino, R. M., Miller, A. H., BREITBART, W. S., Rosenfeld, B. D., & Nelson, C. J. (2020) · Future Oncology · doi:10.2217/fon-2020-0632 · Cited by 36
Inflammation is associated with future depressive symptoms among older adults
Bondy, E., Norton, S. A., Voss, M., Marks, R. B., Boudreaux, M. J., Treadway, M. T., Oltmanns, T. F., & Bogdan, R. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100226 · Cited by 38
Immunoregulation and antidepressant effect of ketamine
Zhang, N., Yao, L., Wang, P., & Liu, Z. (2021) · Translational Neuroscience · doi:10.1515/tnsci-2020-0167 · Cited by 36
Furuyashiki, T., & Kitaoka, S. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12901 · Cited by 37
Yang, L., Huang, Y., Chen, F., Wang, Y., Su, K., Zhao, M., Tao, W., & Liu, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110808 · Cited by 35
Major depressive disorders accompanying autoimmune diseases – Response to treatment
Białek, K. I., Czarny, P. L., Strycharz, J., & Śliwiński, T. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109678 · Cited by 34
Update on Statin Treatment in Patients with Neuropsychiatric Disorders
Avan, R., Sahebnasagh, A., Hashemi, J., Monajati, M., Faramarzi, F., Henney, N. C., Montecucco, F., Jamialahmadi, T., & Sahebkar, A. (2021) · Life · doi:10.3390/life11121365 · Cited by 35
Pain, Depression and Inflammation: Are Interconnected Causative Factors Involved?
Leonard, B. E. (2015) · Modern trends in psychiatry · doi:10.1159/000435930 · Cited by 36
Saleh, L. A., Hamza, M., Gayar, N. H. E., El-Samad, A. A. A., Nasr, E. A., & Masoud, S. I. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.07.013 · Cited by 38
Serum Cytokine Levels in Major Depressive Disorder and Its Role in Antidepressant Response
Myung, W., Lim, S.-W., Woo, H. I., Park, J. H., Shim, S., Lee, S.-Y., & Kim, D. K. (2016) · Psychiatry Investigation · doi:10.4306/pi.2016.13.6.644 · Cited by 33
Tillmann, T., Krishnadas, R., Cavanagh, J., & Petrides, K. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4204 · Cited by 33
“inflammatory component [32], allowing anti-inflammatories to be used as effective adjuncts in the treatment of resistant depression [33,34].”
BackgroundXu, R., & Wang, Q. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.06.027 · Cited by 34
A multispecies approach for understanding neuroimmune mechanisms of stress
Deak, T., Kudinova, A. Y., Lovelock, D. F., Gibb, B. E., & Hennessy, M. B. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.1/tdeak · Cited by 37
Melas, P. A., Lennartsson, A., Vakifahmetoglu-Norberg, H., Wei, Y. B., Åberg, E., Werme, M. J. H., Rogdaki, M., Mannervik, M., Wegener, G., Brené, S., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.31 · Cited by 36
Functional Polymorphism of Cyclooxygenase-2 Gene (G–765C) in Depressive Patients
Gałecki, P., Florkowski, A., Bieńkiewicz, M., & Szemraj, J. (2010) · Neuropsychobiology · doi:10.1159/000317284 · Cited by 32
A Reciprocal Link Between Gut Microbiota, Inflammation and Depression: A Place for Probiotics?
Eltokhi, A., & Sommer, I. E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.852506 · Cited by 36
Childhood maltreatment and adult proinflammatory status in patients with major depression.
Zeugmann, S., Bührsch, N., Bajbouj, M., Heuser, I., Anghelescu, I. G., & Quante, A. (2013) · PubMed · Cited by 36
Anti-Inflammatory Drugs in Psychiatry
Berthold-Losleben, M., Heitmann, S., & Himmerich, H. (2009) · Inflammation & Allergy-Drug Targets · doi:10.2174/187152809789352221 · Cited by 32
Meloxicam Improves Cognitive Impairment of Diabetic Rats through COX2-PGE2-EPs-cAMP/pPKA Pathway
Li, H., Luo, Y., Xu, Y. D., Lü, Y., Hu, C., Chen, Q., Yang, Y., Ma, J., Zhang, J., Xia, H., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00532 · Cited by 34
Making the Case for Multi-Axis Assessment of Behavioural Problems
Fatjó, J., & Bowen, J. (2020) · Animals · doi:10.3390/ani10030383 · Cited by 34
Do Statins Have Antidepressant Effects?
Köhler-Forsberg, O., Gasse, C., Berk, M., & Østergaard, S. D. (2017) · CNS Drugs · doi:10.1007/s40263-017-0422-3 · Cited by 31
Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders
Perrone, M. G., Centonze, A., Miciaccia, M., Ferorelli, S., & Scilimati, A. (2020) · Molecules · doi:10.3390/molecules25225388 · Cited by 35
R.ROSETTA: an interpretable machine learning framework
Garbulowski, M., Diamanti, K., Smolińska, K., Baltzer, N., Stoll, P., Bornelöv, S., Øhrn, A., Feuk, L., & Komorowski, J. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04049-z · Cited by 38
Strekalova, T. V., Pavlov, D., Трофимов, А. Н., Anthony, D. C., Svistunov, A. A., Proshin, A. T., Umriukhin, A., Lyundup, A. V., Lesch, K., & Cespuglio, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042061 · Cited by 32
Dantas, R. L., Freff, J., Ambrée, O., Beins, E. C., Forstner, A. J., Dannlowski, U., Baune, B. T., Scheu, S., & Alferink, J. (2021) · Cells · doi:10.3390/cells10040941 · Cited by 32
Uz, T., Dimitrijević, N., Imbesi, M., Manev, H., & Manev, R. M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.03.041 · Cited by 33
Inamdar, A., Pich, E. M., Gee, M., Makumi, C. W., Mistry, P. C., Robertson, J., Steinberg, E., Zamuner, S., Learned, S. M., Alexander, R., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114529377 · Cited by 32
Begemann, M., Sargin, D., Rossner, M. J., Bartels, C., Theis, F. J., Wickert, S. P., Stender, N., Fischer, B., Sperling, S., Stawicki, S., et al. (2008) · Molecular Medicine · doi:10.2119/2008-00053.begemann · Cited by 30
Monocyte Chemoattractant Protein-1 Levels Are Associated with Major Depressive Disorder
Proma, M. A., Daria, S., Nahar, Z., Ashraful Islam, S. M., Bhuiyan, M. A., & Islam, M. R. (2022) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2021-0132 · Cited by 29
Clement, H., Vazquez-Costa, J. F., Sommer, O., Heiser, P., Morawietz, H., Hopt, U. T., Schulz, E., & von Dobschütz, E. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0327-5 · Cited by 30
Immunological changes in depression
Srivastava, K., Goyal, S., Kodange, C., & Bhat, P. S. (2017) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_22_18 · Cited by 30
Parsons, C., Roberts, R., & Mills, N. T. (2020) · Child and Adolescent Mental Health · doi:10.1111/camh.12434 · Cited by 31
Zhang, Y., Dong, Y., Zhu, Y., Sun, D., Wang, S., Weng, J., Zhu, Y., Peng, W., Yu, B., & Jiang, Y. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100495 · Cited by 34
Role of Aspirin and Dexamethasone against Experimentally Induced Depression in Rats
Bhatt, S., Shukla, P., Raval, J., & Goswami, S. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12539 · Cited by 30
Furuyashiki, T. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.12r09cp · Cited by 30
Stachowicz, K. (2023) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2023.127226 · Cited by 28
Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression
Henter, I. D., SOUSA, R. T. D., Gold, P. W., Brunoni, A. R., Zarate, C. A., & Machado‐Vieira, R. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1253472 · Cited by 32
Krishnadas, R., Krishnadas, R., & Cavanagh, J. (2011) · Journal of Medical Case Reports · doi:10.1186/1752-1947-5-112 · Cited by 28
Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?
Rahola, J. G. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604533 · Cited by 32
Immunity, Aging, and Geriatric Depression
Morimoto, S. S., & Alexopoulos, G. S. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.02.006 · Cited by 29
Vasiliu, O. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884143 · Cited by 34
Clemente‐Suárez, V. J., Bustamante-Sánchez, Á., Tornero-Aguilera, J. F., Ruisoto, P., & Mielgo‐Ayuso, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415584 · Cited by 29
Heterogeneity in major depressive disorder: The need for biomarker-based personalized treatments
Suseelan, S., & Pinna, G. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2022.09.001 · Cited by 33
Halaris, A. E., & Cook, J. T. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_21 · Cited by 33
Su, W., Hu, T., & Jiang, C. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230809112028 · Cited by 29
Jafari, S., Ashrafizadeh, S.-G., Zeinoddini, A., Rasoulinejad, M., Entezari, P., Seddighi, S., & Akhondzadeh, S. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12287 · Cited by 28
Psychoneuroimmunology: the example of psoriasis.
Moynihan, J. A., Rieder, E. A., & Tausk, F. (2010) · PubMed · Cited by 44
The role of microglia during life span in neuropsychiatric disease — an animal study
Manitz, M. P., Eßlinger, M., Wachholz, S., Plümper, J., Friebe, A., Juckel, G., & Wolf, R. J. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.10.028 · Cited by 32
Abdel‐Bakky, M. S., Amin, E., Faris, T. M., & Abdellatif, A. A. H. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12479 · Cited by 30
The role of depression and neuroimmune axis in the prognosis of cancer patients.
Aldea, M. D., Craciun, L., Tomuleasa, C., & Crivii, C. B. (2014) · PubMed · Cited by 32
Immune System Contributions to the Pathophysiology of Depression
Miller, A. H., & Raison, C. L. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.1.foc36 · Cited by 33
Alozie, E. (2015) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608059768115010014 · Cited by 26
Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression
Mendlewicz, J., Crisafulli, C., Calati, R., Kocabaş, N. A., Massat, I., Linotte, S., Kasper, S. F., Fink, M., Sidoti, A., Scantamburlo, G., et al. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.03.063 · Cited by 29
Wang, M., Peng, C., Jiang, T., Wu, Q., Li, D., & Lu, M. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1330338 · Cited by 26
Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction
Chen, C., Tzeng, N., & Chen, Y.-C. (2010) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2010.07.001 · Cited by 28
Effects of adjunctive inflammatory modulation on IL-1β in treatment resistant bipolar depression
Murata, S., Murphy, M. L. M., Hoppensteadt, D., Fareed, J., Welborn, A., & Halaris, A. E. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.01.004 · Cited by 26
Simon, M. S., Burger, B., Weidinger, E., Arteaga-Henríquez, G., Zill, P., Musil, R., Drexhage, H. A., & Müller, N. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.615261 · Cited by 26
Self-citationNLRP3 inflammatory pathway. Can we unlock depression?
Jahromi, G. G., Razi, S., & Rezaei, N. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148644 · Cited by 26
Psychological Factors Associated with Response to Treatment in Rheumatoid Arthritis
Santiago, T., Geenen, R., Jacobs, J. W. G., & Da, J. A. P. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140825124755 · Cited by 28
Deng, Y., Zhao, M., Xu, T., Jin-Hou, & Li, X. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0246-y · Cited by 24
Inflammatory markers and incident depression: evidence in a population-based prospective study
Shi, R., Gwee, X., Chua, D. Q., Tan, C. T., Yap, K. B., Larbi, A., Lu, Y., & Ng, T. P. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105806 · Cited by 23
Molecular and Cellular Aspects of Major Depressive Disorder
Chottekalapanda, R. U., Greengard, P., & Sagi, Y. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780190455132.003.0004 · Cited by 23
Yuluğ, B., Hanoğlu, L., Tavlı, A. M., lmaz, N. H. Y., & c, E. K. L. (2016) · Medicinal Chemistry · doi:10.2174/1573406411666151005110321 · Cited by 24
Bay-Richter, C., Janelidze, S., Sauro, A., Bucala, R., Lipton, J. W., Deierborg, T., & Brundin, L. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0387-4 · Cited by 23
Sorri, A., Järventausta, K., Kampman, O., Lehtimäki, K. A., Björkqvist, M., Tuohimaa, K., Hämäläinen, M., Moilanen, E., & Leinonen, E. V. J. (2018) · Brain and Behavior · doi:10.1002/brb3.933 · Cited by 30
Singh, L., Kaur, A., Garg, S., & Bhatti, R. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00604-4 · Cited by 23
Pharmacogenomics of neuroimmune interactions in human psychiatric disorders
Licinio, J., Mastronardi, C., & Wong, M. (2007) · Experimental Physiology · doi:10.1113/expphysiol.2007.038471 · Cited by 23
“The fact that sickness-like behaviour can be elicited by both pro-inflammatory cytokines and MDD supports the concept that common molecular pathways are shared by inflammation and neuropsychiatric disorders.”
InfluentialMukhtar, I. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111135 · Cited by 22
Managing epilepsy-associated depression: Serotonin enhancers or serotonin producers?
Singh, T., & Goel, R. K. (2016) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.10.007 · Cited by 23
Inflammation Effects on Glutamate as a Pathway to Neuroprogression in Mood Disorders
Haroon, E., & Miller, A. H. (2017) · Modern trends in psychiatry · doi:10.1159/000470805 · Cited by 22
Possible involvement of nitric oxide in antidepressant-like effect of silymarin in male mice
Khoshnoodi, M., Fakhraei, N., & Dehpour, A. R. (2014) · Pharmaceutical Biology · doi:10.3109/13880209.2014.942787 · Cited by 22
Naproxen attenuates sensitization of depressive-like behavior and fever during maternal separation
Hennessy, M. B., Stafford, N. P., Yusko, B., Schiml, P. A., Xanthos, E. D., & Deak, T. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.11.030 · Cited by 22
Inflammation and Mood Disorders: Proinflammatory Cytokines and the Pathogenesis of Depression
Currier, M. B., & Nemeroff, C. B. (2010) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523011009030212 · Cited by 28
Sub-chronic celecoxib prevents soluble beta amyloid-induced depressive-like behaviour in rats
Morgese, M. G., Schiavone, S., Bové, M., Mhillaj, E., Tucci, P., & Trabace, L. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.05.030 · Cited by 23
Allison, D. J., Sharma, B., & Timmons, B. W. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.05.006 · Cited by 25
Wilkinson, B., Trick, L., Knight, A. R., Valton, V., Goodhand, J., Kennedy, N. A., Heerasing, N. M., Ahmad, T., Bland, A. R., Elliott, R., et al. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13647 · Cited by 26
Nie, X., Kitaoka, S., Shinohara, M., Kakizuka, A., Narumiya, S., & Furuyashiki, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-54082-5 · Cited by 27
Chávez-Castillo, M., Nava, M., Ortega, Á., Rojas, M., Núñez, V., Salazar, J. J., Bermúdez, V., & Rojas, J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200413144401 · Cited by 24
Qi, Y., Lu, Y.-R., Shi, L., Demmers, J., Bezstarosti, K., Rijkers, E., Balesar, R. A., Swaab, D. F., & Bao, A. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02040-7 · Cited by 21
Neurochemical and behavioral responses to inflammatory immune stressors
Anisman, H. (2009) · Frontiers in Bioscience-Scholar · doi:10.2741/s26 · Cited by 22
Zhang, T., Yang, C., Chu, J., Ning, L., Zeng, P. H., Wang, X., Shi, Y., Qin, B., Qu, N., Zhang, Q., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696619 · Cited by 22
Dogaru, I.-A., Puiu, M. G., Manea, M., & Dionisie, V. (2022) · Brain Sciences · doi:10.3390/brainsci12101403 · Cited by 23
Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System
Hestad, K. A., Aukrust, P., Tønseth, S., & Reitan, S. K. (2009) · Current Psychiatry Reviews · doi:10.2174/157340009789542105 · Cited by 22
Kennedy, S. H., Young, A. H., & Blier, P. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.048 · Cited by 20
Nassar, A., Sharon-Granit, Y., & Azab, A. N. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.05.019 · Cited by 20
Elnahas, E. M., Zeid, M. S. A., Kawy, H. S. A., Hendawy, N., & Baher, W. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.08.027 · Cited by 21
Kirsten, T. B., Cabral, D., Galvão, M. C., Monteiro, R., Bondan, E. F., & Bernardi, M. M. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.01.019 · Cited by 23
Behavioral Neurobiology of Bipolar Disorder and its Treatment
Manji, H. K., & Zarate, C. A. (2010) · Current topics in behavioral neurosciences · doi:10.1007/978-3-642-15757-8 · Cited by 23
Metadata
- Authors
- Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., Möller, H.-J., Arolt, V, & Riedel, M.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University of Münster (DE)
- Corresponding author
- Müller, N
- Venue
- Molecular Psychiatry
- Published
- 2006-02-21
- Volume
- 11
- Issue
- 7
- Pages
- 680-684
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2049808835
- Cited by
- 794
- References
- 37
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 24 · 2023: 30 · 2022: 42 · 2021: 42 · 2020: 37 · 2019: 44 · 2018: 52 · 2017: 45 · 2016: 42 · 2015: 54 · 2014: 53 · 2013: 61 · 2012: 50
- FWCI
- 20.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- celecoxib, COX-2 inhibitors, major depressive disorder, reboxetine, anti-inflammatory therapy, inflammatory cytokines, prostaglandin E2, adjunctive therapy, acute depressive episode
- MeSH terms
- Celecoxib, Reboxetine, Adult, Antidepressive Agents, Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Inflammation, Lorazepam, Male, Middle Aged, Morpholines, Patient Dropouts, Pilot Projects, Psychological Tests, Pyrazoles, Serotonin, Severity of Illness Index, Sulfonamides, Anti-Anxiety Agents, Dinoprostone, Interleukin-6, Adrenergic Uptake Inhibitors, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.